Author:
Sato Toyoji,Kaneko Takushi,Ishikawa Naoko,Toyama Takako,Enomoto Shinichi,Ohashi Tatsuya,Shima Yukio,Kimura Akira,Hatano Hiroshi,Uchiyama Toru,Segawa Hiroyuki,Kobayashi Hiroto,Morita Tetsuro
Publisher
Japanese Electrophoresis Society
Subject
General Chemical Engineering
Reference15 articles.
1. 1) Jaffe N, Paed D, Farber S, Traggis D, Geiser C, Kim BS, Das L, Frauenberger G, Djerassi I, Cassady JR. Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapy. Cancer 1973;31:1367-1373.
2. 2) Djerassi I. High-dose methotrexate (NSC-740) and Citrovorum factor (NSC-3590) rescue: background and rationale. Cancer Chemother Rep 1975;6:3-6.
3. 3) Jaffe N, Traggis D. Toxicity of high-dose methotrexate (NSC-740) and Citrovorumfactor (NSC-3590) in osteogenic sarcoma. Cancer Chemother Rep 1975;6:31936.
4. 4) Frei E, Jaffe N, Pitman S, Parker L. New approaches to cancer chemotherapy with methotrexate. N Engl J Med 1975;292:846-851.
5. 5) Muraki S, Takahashi T, Ikeda T. Studies of urinary pH, plasma (immunosuppressive acidic protein, sialic acid), urine and plasma (amylase, N-acetyl-β-D-glucosaminidase) during high-dose methotrexate therapy for osteosarcoma. Jpn J Clin Chem 1986;15:225-232.